文献速递消化系统肿瘤

III期CodeBreaK 300研究总生存分析:索托拉西布联合帕尼单抗对比研究者选择方案治疗化疗难治性KRAS G12C结直肠癌

Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2025-04-11

CodeBreaK 300研究纳入160例化疗难治性KRAS G12C突变转移性结直肠癌患者,随机接受索托拉西布960mg联合帕尼单抗、索托拉西布240mg联合帕尼单抗或研究者选择方案。中位随访13.6个月,总生存风险比分别为0.70和0.83,均未达统计学显著,但观察到的总生存风险比、客观缓解率及既往无进展生存和安全性结果支持索托拉西布960mg联合帕尼单抗作为标准治疗。

要点

  • 索托拉西布960mg联合帕尼单抗组客观缓解率为30.2%,高于研究者选择组的1.9%。
  • 索托拉西布960mg联合帕尼单抗对比研究者选择方案的总生存风险比为0.70,未达统计学显著。
  • 观察到的总生存风险比、客观缓解率及既往无进展生存和安全性结果支持索托拉西布960mg联合帕尼单抗作为标准治疗。

核心结论

  • 尽管总生存未达统计学显著,观察到的总生存风险比和客观缓解率以及既往无进展生存和安全性结果支持索托拉西布960mg联合帕尼单抗作为化疗难治性KRAS G12C突变转移性结直肠癌患者的标准治疗。

研究设计与样本

  • III期CodeBreaK 300研究将160例化疗难治性KRAS G12C突变转移性结直肠癌患者按1:1:1随机分配至索托拉西布960mg联合帕尼单抗组(n=53)、索托拉西布240mg联合帕尼单抗组(n=53)或研究者选择组(n=54;主要分析后允许交叉)。
  • 总生存分析为关键次要终点,虽未充分把握度,但预设于50%成熟度(约80例死亡后)进行。

主要发现

  • 中位随访13.6个月后,索托拉西布960mg联合帕尼单抗组、索托拉西布240mg联合帕尼单抗组和研究者选择组分别发生24、28和30例死亡。
  • 更新后的客观缓解率(95%CI)分别为30.2%(95%CI,18.3至44.3)、7.5%(95%CI,2.1至18.2)和1.9%(95%CI,0.0至9.9)。
  • 对比研究者选择组,索托拉西布960mg联合帕尼单抗组的总生存风险比为0.70(95%CI,0.41至1.18;双侧P=0.20),索托拉西布240mg联合帕尼单抗组为0.83(95%CI,0.49至1.39;双侧P=0.50)。
  • 未观察到新的安全性信号。

临床怎么用

  • 作者认为,尽管未达统计学显著,观察到的总生存风险比和客观缓解率以及既往无进展生存和安全性结果支持索托拉西布960mg联合帕尼单抗作为化疗难治性KRAS G12C突变转移性结直肠癌患者的标准治疗。

局限性

  • 总生存分析虽为预设的关键次要终点,但未充分把握度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In the phase III CodeBreaK 300 study, sotorasib 960 mg-panitumumab significantly prolonged progression-free survival (PFS) versus investigator's choice (trifluridine/tipiracil or regorafenib) in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer (mCRC). One hundred sixty patients were randomly assigned 1:1:1 to receive sotorasib 960 mg-panitumumab (n = 53), sotorasib 240 mg-panitumumab (n = 53), or investigator's choice (n = 54; crossover permitted after primary analysis). Overall survival (OS) analysis, a key secondary end point, although not adequately powered, was prespecified at 50% maturity (after approximately 80 deaths). In this study, we report the OS, updated overall response rates (ORRs), and data for safety. After a median follow-up of 13.6 months, 24, 28, and 30 deaths occurred in the sotorasib 960 mg-panitumumab, sotorasib 240 mg-panitumumab, and investigator's choice arms, respectively; updated objective response rates (ORRs; 95% CI) were 30.2% (95% CI, 18.3 to 44.3), 7.5% (95% CI, 2.1 to 18.2), and 1.9% (95% CI, 0.0 to 9.9), respectively. Compared with investigator's choice, the hazard ratios (HRs [95% CI]) for OS were 0.70 (95% CI, 0.41 to 1.18; two-sided P = .20) with sotorasib 960 mg-panitumumab and 0.83 (95% CI, 0.49 to 1.39; two-sided P = .50) with sotorasib 240 mg-panitumumab. No new safety signals were observed. Although not statistically significant, the observed OS HR and ORR along with prior PFS and safety findings support sotorasib 960 mg-panitumumab as a standard of care in patients with chemorefractory KRAS G12C mCRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pietrantonio F, Salvatore L, Esaki T, et al. Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer. J Clin Oncol. 2025. PMID: 40215429. doi:10.1200/JCO-24-02026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。